At a glance
ClinicalIndex Comparison RecordN/ACompleted· 220 enrolled
Drug / intervention
Mebeverinedrug
Likely dose
Mebeverine 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness of Duspatalin® (Mebeverine Hydrochloride) 200 mg b.i.d. in Patients With Post-cholecystectomy Gastrointestinal Spasm: a Post Marketing Observational Program in the Russian Federation
In Brief
An observational study evaluating Mebeverine for Post-cholecystectomy Gastrointestinal Spasms. Completed, enrolled 220 participants across 21 sites.
Detailed Summary
Prospective, multicenter, non-comparative, observational program designed to assess the effectiveness of a 2-6 weeks treatment with Duspatalin® 200mg bis in die = twice a day (BID) and changes in quality of life in patients with post-cholecystectomy gastro-intestinal spasms
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesRussia
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartJul 2015
Primary CompletionOct 2016
TodayJul 2026
First PostedOct 9, 2014
Enrollment StartJul 1, 2015
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.7 years ago
Interventions
Mebeverinedrug
Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed